Project Grant R43GM150366
Award Date
9/19/24
Completion Date
9/18/25
Dollars Obligated
$283K
Federal Agency
National Institute of General Medical Sciences
Awardee
Lynntech Inc. (PMVAL8J63516)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Sxrna Technologies, Inc. to develop a rapid cloning technology called SXRNA-SELECT. This technology aims to decrease the time required to clone mammalian cells and increase protein yields for biotherapeutic production. The key objectives are to optimize the delivery protocol for plasmids and SXRNA-bait, demonstrate selection...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...
This Project Grant award, valued at $936,000.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) federal grant program. The goal of this project is to develop a platform called mRNADesigner, an integrated deep learning model to optimize the 5'UTR, codon usage, and 3'UTR of mRNA sequences simultaneously. This will enable users to design optimal mRNA sequences to enhance protein expression levels and...
The National Institute of General Medical Sciences (NIGMS) awarded a $300,518 Project Grant under CFDA Program 93.859 (Biomedical Research and Research Training) to E&E Bioclub LLC in Indianapolis, IN. The project aims to develop an all-in-one platform for intracellular overproduction of long, single-strand mRNA. This is intended to address challenges with current mRNA manufacturing methods, such as the cost and scalability constraints of in vitro transcription and the difficulty in...
This Project Grant award, with ID R01GM157259, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award, totaling $337,088, supports the development of a versatile platform for RNA delivery specifically tailored for the central nervous system (CNS). The key objectives are to establish a delivery system capable of high-efficiency RNA transfer, precise cell-specific targeting, and minimal...
The National Institute of General Medical Sciences (NIGMS) awarded a $313,520 Project Grant (CFDA 93.859 Biomedical Research and Research Training) to the Regents of the University of Michigan to develop the RNP-MAP technology into a broad-spectrum toolset for discovering, defining, and targeting RNA-protein complexes in live cells. The 5-year project aims to create new methods for 1) mapping multi-protein networks on RNA, 2) mapping transcriptome-wide targets of RNA-binding proteins, and 3)...
This $3,000,000 project grant, awarded by the National Science Foundation (NSF) under the Engineering (CFDA 47.041) program, aims to solve the long-standing challenge of developing self-amplifying ribonucleic acid (SARNA) technologies. The project, led by Trustees of Boston University, a private non-profit research university, will: Synthesize a diverse library of modified nucleoside triphosphates (ModNTPs) and use them to produce modified SARNA with extended cellular half-life. Evaluate the...
The National Institute of General Medical Sciences (NIGMS) awarded a $700,000 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) program to Mirimus, Inc., a self-certified small disadvantaged business located in Brooklyn, NY. The grant funding, with a period of performance from September 20, 2024 to April 19, 2025, will support the creation of next-generation RNA interference (RNAi) therapeutics and the development of an in vivo mouse model to evaluate their efficacy...
This federal Project Grant award of $324,998 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program supports Rejuvenation Technologies Inc. (RTI) in developing advanced therapeutic technologies for in vivo delivery of mRNA to stem and progenitor cells. The key objectives of this award are to: 1) generate a library of rationally designed peptides for targeting three progenitor cell types, 2) utilize computational...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...